The evaluation of the clinical features of patients with non-Hodgkin lymphoma
Küçük Resim Yok
Tarih
2006
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The clinical features, histopathological types, treatment modalities and response, and survival analysis were evaluated in our 114 patients with non-Hodgkin lymphoma (NHL). At initial diagnosis, 10% had stage I, 14% stage II, 30% stage III, and 46% stage IV disease according to Cotswold classification. Therapy was administered to 101 (89%) NHL subjects at initial diagnosis. CHOP was given to 57 (56%) and rituximab (R)-CHOP to 17 (17%) cases. The highest rate of complete remission was in R-CHOP group (83%). The median survival of NHL subjects was 52 months. 3-year survival was 54%, 5-year survival was 46%. Survival of very aggressive lymphoma patients (3 months) was shorter than that of aggressive (41 months) and indolent (86 months) patients (p values<0.05). The median survival of stage IV subjects at initial diagnosis (26 months) was shorter than stage I (not reached), stage II (86 months) and stage III (96 months) cases (p values<0.05). Survival of patients with B symptoms, extranodal and bone marrow involvement, unresponsive to first-line therapy, IPI>2 at initial diagnosis was shorter than others (p values <0.05). Cox regression analysis showed that unresponsiveness to first-line therapy (OR:11.6, p=0.001) was an independent poor prognostic factor. It was interesting that combined chemotherapy with rituximab achieved a high rate of complete remission when given as first-line therapy.
Açıklama
Anahtar Kelimeler
Chop; Non-Hodgkin Lymphoma; Prognosis; Rituximab, Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine; Adult; Aged; Article; Bone Marrow Metastasis; Cancer Chemotherapy; Cancer Regression; Cancer Staging; Cancer Survival; Clinical Evaluation; Clinical Feature; Controlled Study; Female; Histopathology; Human; Human Tissue; Major Clinical Study; Male; Nonhodgkin Lymphoma; Outcome Assessment; Primary Health Care; Prognosis; Proportional Hazards Model; Treatment Response
Kaynak
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
16
Sayı
4
